At the Community Oncology Global Congress (COGC 2026), organized by OncoDaily, Amol Akhade, Senior Consultant in Medical ...
COCOON shows lazertinib lead-in plus simplified prophylaxis reduced grade ≥2 skin toxicity to 18% with SC amivantamab in EGFR ...
FLAURA2 shows early EGFR ctDNA clearance is prognostic but does not predict benefit from adding chemotherapy to first-line ...
VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...
MONARCH shows median OS of 32.1 vs 24.6 months with abemaciclib after prior CDK4/6 therapy, but the survival difference was ...
SHR-A2102 at ESMO 2026 Shows 47.2% Response Rate in Recurrent or Metastatic Cervical Cancer / cancer, ESMO, esmo 2026, ...
HBI-8000-303 evaluates the HDAC inhibitor HBI-8000 plus nivolumab in advanced melanoma, examining PFS, response, safety, and ...
Daraxonrasib Versus Chemotherapy in Metastatic Pancreatic Cancer – Additional Subgroup Analyses / cancer, cancer care, Cancer ...
Mongolia’s Former Minister of Health Dr Chinburen Jigjidsuren Will Join the International Advisory Board of Dr Gevorg ...
Celebrating 8 Community Members Elected to the National Academy of Medicine - The Mark Foundation for Cancer Research / ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
Two Worlds Cancer Collaboration Session on Global Palliative Care - London Global Cancer Week 2026 / cancer, health care, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results